drugset / Trial / NCT04631601
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
RandomizedSequentialOpen-labelTreatment
Summary
This is a master protocol designed to evaluate the safety and efficacy of investigational therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).
Timeline
- Start
- 2021-01-15
- Primary completion
- 2023-10-23
- Completion
- 2023-10-23
Outcome
Outcome not reported
Stopped (Business): “Amgen made a business decision to discontinue all AMG 160 clinical trials. This decision is not related to safety.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMG 404 | Monoclonal antibody | — | Intravenous |
| Subject | Abiraterone acetate | Small molecule | — | Oral |
| Subject | Acapatamab | Monoclonal antibody | — | Intravenous |
| Subject | Enzalutamide | Other / unclassified | — | Oral |